Profile data is unavailable for this security.
About the company
Exicure, Inc. is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The Company is into exploring strategic alternatives to maximize stockholder value. It is engaging in a broader exploration of strategic alternatives. This effort involves exploring growth through transactions with potential partners that see opportunity in joining an existing, publicly traded organization. The Company is exploring transactions in industries unrelated to its historical operations. It does not generate any revenues. It wholly owned subsidiary is Exicure Operating Company that holds all material assets and conducts all business activities and operations of the Company.
- Revenue in USD (TTM)500.00k
- Net income in USD-13.34m
- Incorporated2017
- Employees6.00
- LocationExicure Inc2430 N. HALSTED ST.CHICAGO 60614United StatesUSA
- Phone+1 (847) 673-1700
- Fax+1 (847) 556-6411
- Websitehttps://www.exicuretx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cyclacel Pharmaceuticals Inc | 449.00k | -19.85m | 2.36m | 12.00 | -- | -- | -- | 5.25 | -21.99 | -21.99 | 0.4636 | -1.67 | 0.0318 | -- | 0.1204 | -- | -139.57 | -57.58 | -314.22 | -69.81 | -- | -- | -4,386.86 | -18,789.29 | -- | -128.51 | -- | -- | -- | 22.87 | -6.34 | -- | -31.23 | -- |
| Eloxx Pharmaceuticals Inc | 0.00 | -20.48m | 2.36m | 18.00 | -- | -- | -- | -- | -9.06 | -9.06 | 0.00 | -6.53 | 0.00 | -- | -- | 0.00 | -124.43 | -115.27 | -- | -155.33 | -- | -- | -- | -- | -- | -16.69 | -- | -- | -- | -- | 45.95 | -- | -22.56 | -- |
| Aclarion Inc | 60.05k | -6.13m | 2.38m | 6.00 | -- | 0.83 | -- | 39.71 | -7.41 | -7.41 | 0.0341 | 0.3502 | 0.0215 | -- | 3.50 | 10,008.33 | -219.26 | -- | -337.53 | -- | -29.49 | -- | -10,203.20 | -- | -- | -- | 0.211 | -- | 24.75 | -- | 34.38 | -- | -- | -- |
| Regen BioPharma Inc | 236.58k | -851.69k | 2.47m | 1.00 | -- | -- | -- | 10.44 | -0.2271 | -0.2271 | 0.0633 | -1.26 | 0.8644 | -- | 3.98 | 236,580.00 | -327.54 | -104.36 | -- | -- | -- | -- | -378.93 | -275.00 | -- | -1.32 | -- | -- | 0.4416 | 18.79 | -58.11 | -- | -- | -- |
| Cingulate Inc | 0.00 | -22.50m | 2.48m | 13.00 | -- | 0.5252 | -- | -- | -22.66 | -22.66 | 0.00 | 0.6419 | 0.00 | -- | -- | 0.00 | -355.56 | -- | -1,198.96 | -- | -- | -- | -- | -- | -- | -33.88 | 0.0054 | -- | -- | -- | -33.14 | -- | -- | -- |
| Qrons Inc | 0.00 | -763.52k | 2.53m | 2.00 | -- | -- | -- | -- | -0.0562 | -0.0562 | 0.00 | -0.1078 | 0.00 | -- | -- | 0.00 | -18,782.78 | -1,513.45 | -- | -- | -- | -- | -- | -- | -- | -19.02 | -- | -- | -- | -- | -7.61 | -- | -- | -- |
| SenesTech Inc | 1.38m | -7.51m | 2.55m | 25.00 | -- | 0.5524 | -- | 1.85 | -15.21 | -15.21 | 0.7189 | 0.8961 | 0.2718 | 0.939 | 13.29 | 55,000.00 | -148.36 | -118.53 | -178.99 | -140.61 | 42.33 | 39.40 | -545.82 | -1,357.86 | 5.69 | -- | 0.0378 | -- | 17.08 | 32.06 | 20.47 | -- | -9.02 | -- |
| Exicure Inc | 500.00k | -13.34m | 2.61m | 6.00 | -- | 1.18 | -- | 5.21 | -1.56 | -1.56 | 0.0582 | 0.2551 | 0.0289 | -- | -- | 83,333.34 | -76.97 | -41.52 | -91.14 | -55.78 | -- | -- | -2,667.20 | -290.95 | -- | -- | 0.00 | -- | -100.00 | -- | -555.07 | -- | -- | -- |
| Entero Therapeutics Inc | 0.00 | -6.44m | 2.65m | 15.00 | -- | 0.1339 | -- | -- | -51.90 | -51.90 | 0.00 | 38.45 | 0.00 | -- | -- | 0.00 | -12.74 | -295.92 | -14.01 | -1,599.51 | -- | -- | -- | -- | -- | -265.69 | 0.0802 | -- | -- | -- | -7.55 | -- | -- | -- |
| Tharimmune Inc | 0.00 | -8.89m | 2.67m | 2.00 | -- | 0.3791 | -- | -- | -111.65 | -111.65 | 0.00 | 8.97 | 0.00 | -- | -- | 0.00 | -130.60 | -- | -173.40 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.98 | -- | -- | -- |
| Qualigen Therapeutics Inc | 0.00 | -12.48m | 2.69m | 4.00 | -- | -- | -- | -- | -2.46 | -2.64 | 0.00 | -0.3923 | 0.00 | -- | -- | 0.00 | -118.15 | -- | -364.72 | -- | 21.30 | -- | -- | -- | -- | -7.41 | -- | -- | -- | -- | 10.22 | -- | -- | -- |
| Tron Pharmaceuticals Inc | 1.01m | -549.47k | 2.75m | 50.00 | -- | -- | -- | 2.73 | -0.0034 | -0.0034 | 0.0062 | -0.0508 | -- | -- | -- | 20,191.00 | -- | -- | -- | -- | 60.28 | -- | -110.51 | -- | 0.0417 | -433.32 | -- | -- | 0.3272 | -- | -39.70 | -- | -- | -- |
| Revelation Biosciences Inc | 0.00 | -8.96m | 2.82m | 9.00 | -- | 0.2982 | -- | -- | -32.09 | -32.09 | 0.00 | 5.80 | 0.00 | -- | -- | 0.00 | -54.61 | -- | -91.95 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 98.89 | -- | -- | -- |
| Bio Path Holdings Inc | 0.00 | -13.96m | 2.83m | 10.00 | -- | -- | -- | -- | -27.39 | -27.39 | 0.00 | -3.48 | 0.00 | -- | -- | 0.00 | -216.97 | -70.80 | -390.65 | -76.87 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -15.94 | -- | -- | -- |
| Kiromic Biopharma Inc | 0.00 | -24.99m | 2.86m | 31.00 | -- | -- | -- | -- | -29.21 | -29.21 | 0.00 | -3.81 | 0.00 | -- | -- | 0.00 | -171.18 | -161.49 | -- | -213.01 | -- | -- | -- | -- | -- | -15.69 | 1.87 | -- | -- | -- | -35.90 | -- | 177.42 | -- |
Data as of Jul 05 2024. Currency figures normalised to Exicure Inc's reporting currency: US Dollar USD
3.89%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Renaissance Technologies LLCas of 31 Mar 2024 | 65.60k | 0.76% |
| Geode Capital Management LLCas of 31 Mar 2024 | 56.52k | 0.65% |
| Northwestern University (Investment Management)as of 31 Mar 2024 | 52.15k | 0.60% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 40.09k | 0.46% |
| Millennium Management LLCas of 31 Mar 2024 | 34.80k | 0.40% |
| Virtu Americas LLCas of 31 Mar 2024 | 27.04k | 0.31% |
| Two Sigma Securities LLCas of 31 Mar 2024 | 22.70k | 0.26% |
| Citadel Securities LLCas of 31 Mar 2024 | 18.16k | 0.21% |
| Bank of America, NA (Private Banking)as of 31 Mar 2024 | 12.80k | 0.15% |
| Tower Research Capital LLCas of 31 Mar 2024 | 7.03k | 0.08% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
